3,4-Dimethoxy Phenylethylamine

Product name:3,4-Dimethoxy Phenylethylamine
CAS: 120-20-7
Molecular Formula:C10H15NO2
Formula Weight:     181.23
Description:
Melting point:12-15 ºC
Boiling point:324.1 ºC at 760 mmHg
Flash Point:132.8 ºC
Density:1.074 g/mL at 25 °C(lit.)
Chemical property:Colorless transparent liquid.Soluble in water.
Use:Used as an intermediate in the organic synthesis.

MDA-MB-157

Product name:MDA-MB-157
Species:Human

Gender:Female  

Source:Breast

Morphology: epithelial 

Growth Properties:Adherent growth

Application:
It can be used for breast cancer research.

Culture Media: DMEM, 10%FBS

Halofuginone

Product Name:Halofuginone

CAS:55837-20-2

Molecular Formula:C16H17BrClN3O3

Molecular weight:414.6815

Description:7-bromo-6-chloro-3-{3-[(3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one; 7-bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4(3H)-one; 7-bromo-6-chloro-3-{3-[(2S,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one; 7-bromo-6-chloro-3-{3-[(2R,3S)-3-hydroxypiperidin-2-yl]-2-oxopropyl}quinazolin-4(3H)-one

Spiraeoside

Mast cells are responsible for allergic reactions IgE mediated by the secretion of various inflammatory cytokines and mediators. Thus, pharmacological regulation of mast cell activation is an important goal in developing new anti-allergic drugs. In this study, we found that spiraeoside (SP) and inhibits the activation of allergic reactions in vivo mast cells. dose-dependently inhibited SP-induced degranulation by IgE-antigen (Ag) in the stimulation of RBL-2H3 mast cells without cytotoxic effects. At the molecular level SP reduced Ag-induced phosphorylation and subsequent activation of phospholipase C-γ2 (PLC-γ2). SP also inhibited tyrosine kinase phosphorylation spleen (Syk), linker for activation of T cells (LAT) and downstream MAPK ERK1 / 2, p38 and JNK optionally attenuation of expression of TNF-α and IL-4. Finally, we found that SP anaphylaxis clearly IgE-mediated passive cutaneous (PCA) in the inhibited mouse. Taken together, our results suggest that activation suppressed SP IgE-mediated mast cell and allergic reactions by inhibiting the signaling / MAPK PLC-γ2 Lyn-induced in mast cells.

Cyclic acid for sale

Product Name: Cyclic Acid
CAS no. 59564-78-2
Molecular formula: C19H18N2O5
Molecular Weight: 354.36
Appearance: yellowish white or white crystalline powder
Purity: not less than98.0%
Product Description: This product is through vitamin H (biotin-D), we can ago.now developed by our years of business annually produce 500MT cyclic acid. Due to the excellent quality and leading technologies, this product is very popular with Chinese manufacturers.

Dapagliflozin for sale

Product Name: dapagliflozin
CAS: 461432-26-8
Molecular formula: C21H25ClO6
Molecular Weight: 408.875
Product Description: By inhibiting sodium - glucose transporter (SGLT2) - two kidneys in a make glucose absorbed into the bloodstream proteins, and play a role. He also made redundant glucose excreted in the urine, so under the condition without increasing insulin to improve glycemic control. Use this medication for patients with normal renal function after severe renal impairment in patients. This product can be reduced significantly with the type 2 diabetes HbA1c and fasting glucose levels, the incidence of adverse effects similar to placebo, a low risk of hypoglycemia in alone or in combination with metformin, pioglitazone, Glenn urea, insulin and other drugs used in combination patient weight can be reduced.

Streptokinase Abstract

A chance discovery by William Smith Tillett 1933, followed by many years of work with Sol Sherry students has laid a solid foundation for the use of streptokinase as thrombolytic agents in the treatment of acute myocardial infarction. Drugs found first clinical application in the control of fibrinous pleural effusion, hemothorax and tuberculous meningitis. In 1958, Sherry and others began streptokinase in patients with acute myocardial infarction with and changed the bleaching treatment center "cure" for. The first attempts to streptokinase infusion contradictory results used. An innovative approach to intracoronary streptokinase infusion was 1979 and larger intracoronary infusion studies have achieved patency rates of 70% to 90% of Rentrop and his colleagues began. The need for a multicenter randomized systematic and carefully planned was conducted filled by the sperimentazione della streptokinase dell'Infarto Miocardico Gruppo Italiano per study (GISSI) in 1986, which not only valid streptokinase as an effective therapeutic method, but also established a solid record for use in acute myocardial infarction. Currently, despite the widespread use of tissue plasminogen activator, streptokinase in industrialized countries remains essential for the treatment of acute myocardial infarction in developing countries.